AARDEX Group

AARDEX Group will be at the 2nd value added medicines conference 2018

medicines
NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines

NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines conference, Brussels, November 21, 2018

This event is organized by Medicines for Europe about ” an innovative approach for patients’ future”.

More on https://www.medicinesforeurope.com/events/vam2018/

Share This Post

You may also like...

Breaking News

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological

Bias in clinical Research
Breaking News

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,